First established by French immunologist Daniel Zagury, M.D, PhD., as a spinoff of Pierre et Marie Curie University. Neovacs became a biotechnology company in 2003 when several investment funds specialized in healthcare industry joined the capital.
Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune, inflammatory diseases, allergies and cancers.
IFNα Kinoid: this “anti-interferon-alpha” vaccine, is now the most advanced product of Neovacs research. It is currently in clinical development in lupus and dermatomyositis.
3-5, Impasse Reille
Tel. : 33 (0)1 53 10 93 00
Fax : 33 (0)1 53 10 93 03
Why should you invest in Neovacs?go to the investors section